Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc., despite the metadata request) on March 26, 2025, with a signature date of March 28, 2025. The filing addresses two primary events: an amendment to a previously announced merger agreement with Decoy Therapeutics Inc. and a notice from Nasdaq regarding non-compliance with listing standards.
Key Financial Metrics and Liquidity
The filing does not provide specific revenue, profit, or cash flow figures for the current period. However, it discloses the following financial conditions:
- Stockholders' Equity: The Company failed to meet the Nasdaq minimum requirement of $2.5 million in stockholders' equity based on its Form 10-K for the year ended December 31, 2024.
- Qualified Financing Requirement: The proposed merger closing is conditioned on raising minimum proceeds of $6.0 million through equity offerings.
- Valuation Assumptions: The merger exchange ratio assumes a base value of $28.0 million for Decoy Therapeutics and $4.6 million for Salarius.
Material Changes and Agreements
Merger Agreement Amendment (Item 1.01): On March 28, 2025, the parties entered into Amendment No. 1 to the Merger Agreement. Key changes include:
- Elimination of Cash Adjustment: The previous provision adjusting the exchange ratio based on relative balance sheet cash at closing has been removed.
- Fixed Ownership Structure: Post-merger ownership is now fixed on a fully-diluted basis (excluding Qualified Financing dilution):
- Decoy Legacy Stockholders: 85.9%
- Salarius Legacy Stockholders: 14.1%
Nasdaq Listing Status (Item 3.01): The Company received a notice of non-compliance with Nasdaq Listing Rule 5550(b)(1) due to insufficient stockholders' equity. It also fails to meet alternative standards for market value of listed securities or net income.
Outlook, Risks, and Contingencies
Compliance Timeline:
- Deadline to Regain Compliance or Submit Plan: May 12, 2025.
- Extension Possibility: If a Compliance Plan is accepted, Nasdaq may grant up to 180 days to regain compliance.
- Delisting Risk: If compliance is not achieved by May 12, 2025, or if an extension is not granted by September 22, 2025, the Company faces potential delisting.
Merger Risks: The closing of the merger is contingent upon the successful completion of the Qualified Financing ($6.0 million) and the continued listing of Salarius common stock on Nasdaq. There is no assurance that the Compliance Plan will be accepted or that the merger will close.
Investor Verification Checklist
- Verify the current status of the $6.0 million Qualified Financing required to close the merger.
- Monitor the Company's submission of a Compliance Plan to Nasdaq by the May 12, 2025 deadline.
- Review the full text of Amendment No. 1 (Exhibit 2.1) for any other modified terms not summarized here.
- Assess the risk of delisting if the Company fails to regain equity compliance or secure the necessary financing.
- Confirm the final ownership percentages post-closing, specifically regarding dilution from the Qualified Financing.